Meta-Research Study on the Quality of Randomized Controlled Trials Evaluating Drug Therapy for Impetigo
Keywords:
Impetigo, Drug therapy, Randomized controlled trials, Methodological quality, Meta-researchAbstract
Introduction: Impetigo is a common, highly contagious bacterial skin infection primarily affecting children. Treatment usually involves topical or oral antibiotics, and numerous clinical trials have been published to support these therapeutic approaches.
Objectives: to evaluate the methodological quality of randomized clinical trials (RCTs) on the pharmacological treatment of impetigo in children and adolescents.
Methods: This meta-research evaluates RCTs on systemic or topical pharmacological treatments for impetigo in children and adolescents. A comprehensive literature search was conducted on September 2024 across MEDLINE, Embase, CENTRAL, and LILACS databases. The methodological quality of the included RCTs was assessed using the Cochrane Risk of Bias tool. Data were presented as percentages.
Results: 21 RCTs on pharmacological treatments for impetigo were identified and assessed. The findings identified some methodological concerns: (i) 53% to 57% of RCTs had an unclear risk of selection bias due to insufficient information on randomization and allocation concealment; (ii) 71% were at high risk of bias for blinding of participants and personnel, while 57% had a high risk for blinding of outcome assessors; (iii) 24% exhibited a high risk of attrition bias due to significant participant losses without justification, and (iv) 81% had an unclear risk of bias due to the lack of registered protocols available.
Conclusions: Based on the methodological quality of the assessed RCTs, this study underscores the need for more rigorous design and reporting standards in future research on pharmacological treatments for impetigo to enhance the reliability and validity of the evidence, thereby supporting more informed clinical decision-making.
References
Page MJ, Higgins JP, Clayton G, Sterne JA, Hróbjartsson A, Savović J. Empirical evidence of study design biases in randomized trials: systematic review of meta-epidemiological studies. PLoS One. 2016 Jul 11;11(7):e0159267. DOI: 10.1371/journal.pone.0159267. PMID: 27398997
Guyatt G, Cairns J, Churchill D, Cook D, Haynes B, Hirsh J, et al. Evidence-based medicine: A new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420–5. DOI: 10.1001/jama.1992.03490170092032. PMID: 1404801
Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence-based medicine: what it is and what it isn't. BMJ [Internet]. 1996 Jan 13;312(7023):71–2. DOI: 10.1136/bmj.312.7023.71. PMID: 8555924
Mansournia MA, Higgins JP, Sterne JA, Hernán MA. Biases in randomized trials: a conversation between trialists and epidemiologists. Epidemiology. 2017 Jan;28(1):54-59. DOI: 10.1097/EDE.0000000000000564. PMID: 27748683
Savović J, Jones H, Altman D, Harris R, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. Health Technol Assess. 2012 Sep;16(35):1-82. DOI: 10.3310/hta16350. PMID: 22989478
Moustgaard H, Clayton GL, Jones HE, Boutron I, Jørgensen L, Laursen DRT, et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. BMJ. 2020 Jan 21;368:l6802. DOI: 10.1136/bmj.l6802. PMID: 31964641
Gahlawat G, Tesfaye W, Bushell M, Abrha S, Peterson GM, Mathew C, et al. Emerging treatment strategies for impetigo in endemic and nonendemic settings: A Systematic Review. Clin Ther. 2021 Jun;43(6):986–1006. DOI: 10.1016/j.clinthera.2021.04.013. PMID: 34053699
Primhak S, Gataua A, Purvis D, Thompson JMD, Walker C, Best E, et al. Treatment of Impetigo with Antiseptics - Replacing Antibiotics (TIARA) trial: a single-blind randomized controlled trial in school health clinics within socioeconomically disadvantaged communities in New Zealand. Trials. 2022 Feb 2;23(1). DOI: 10.1186/s13063-022-06042-0. PMID: 35109906
Murad MH, Wang Z. Guidelines for reporting meta-epidemiological methodology research. Evid Based Med. 2017 Jul;22(4):139–42. DOI: 10.1136/ebmed-2017-110713. PMID: 28701372
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 March 29th;372. Available from: https://www.bmj.com/content/372/bmj.n71. DOI: 10.1136/bmj.n71. PMID: 33782057
Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016 Dec;5(1):210. DOI: 10.1186/s13643-016-0384-4. PMID: 27919275
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011 [cited 2024 August 24th]. Available from: www.cochrane‐handbook.org
Burnett JW. The route of antibiotic administration in superficial impetigo. N Engl J Med [Internet]. 1963 Jan 10;268(2):72–5. DOI: 10.1056/NEJM196301102680203. PMID: 14017141
Ferrieri P, Dajani AS, Wannamaker LW. A controlled study of penicillin prophylaxis against streptococcal impetigo. J Infect Dis. 1974 Apr;129(4):429–38. DOI: 10.1093/infdis/129.4.429. PMID: 4593872
Gropper S, Cepero AL, Santos B, Kruger D. Systemic bioavailability and safety of twice-daily topical ozenoxacin 1% cream in adults and children with impetigo. Future Microbiology. 2014 Aug;9(8s):S33–40. DOI: 10.2217/fmb.14.85. PMID: 25209523
Hebert AA, Rosen T, Albareda López N, Zsolt I, Masramon X. Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo. Int J Womens Dermatol. 2020 Mar;6(2):109–15. DOI: 10.1016/j.ijwd.2019.10.008. PMID: 32258344
Larcombe JH. Review: topical mupirocin or fusidic acid may be more effective than oral antibiotics for limited non-bullous impetigo. Evid Based Med. 2004 Nov;9(6):176. DOI: 10.1136/ebm.9.6.176. PMID: 15688485
Zubair Ahmed F, M V A. Efficacy and cost-effectiveness comparison between fusidic acid and mupirocin for impetigo. IP Int J Compr Adv Pharmacol. 2019 October 15th;4(3):100–4. DOI: 10.18231/j.ijcaap.2019.021
Barton LL, Friedman AS, Portilla MG. Impetigo Contagiosa: A Comparison of Erythromycin and Dicloxacillin Therapy. Pediatr Dermatol. 1988 May;5(2):88–91. DOI: 10.1111/j.1525-1470.1988.tb01144.x. PMID: 3045781
Ciftci E, Guriz H, Aysev AD. Mupirocin vs terbinafine in impetigo. Indian J Pediatr [Internet]. 2002 Aug [cited 2024 Apr 5];69(8):679–82. DOI: 10.1007/BF02722704. PMID: 12356219
Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrobial Agents and Chemotherapy. 1992 Feb;36(2):287–90. DOI: 10.1128/AAC.36.2.287. PMID: 1605593
Dash P, Khan F, Sarda S, Tanwar R. A comparative study of topical 1% ozenoxacin cream and 2% mupirocin cream for the treatment of impetigo in children. Int J Pharm Clin Res. 2023 Nov;15(11):116
Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC. Impetigo: Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child. 1990 Dec;144(12):1313–5. DOI: 10.1001/archpedi.1990.02150360037015. PMID: 2244610
Eells LD, Mertz PM, Piovanetti Y, Pekoe GM, Eaglstein WH. Topical antibiotic treatment of impetigo with mupirocin. Arch Dermatol. 1986 Nov;122(11):1273-6. PMID: 3096221.Goldfarb J, Crenshaw D, O’Horo J, Lemon E, Blumer JL. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrobial Agents and Chemotherapy. 1988 Dec 1;32(12):1780–3. DOI: 10.1128/AAC.32.12.1780. PMID: 3149884
Gropper S, Albareda N, Chelius K, Kruger D, Mitha I, Vahed Y, et al. Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. Future Microbiology. 2014 Sep;9(9):1013–23. DOI: 10.2217/fmb.14.78. PMID: 25340832
Iovino SM, Krantz KD, Blanco DM, Fernández JA, Ocampo N, Najafi A, et al. NVC-422 topical gel for the treatment of impetigo. International journal of clinical and experimental pathology [Internet]. 2011 [cited 2024 Aug 24];4(6):587–95. PMID: 21904634
Jeffrey LT, Britton W, J. Eduardo Fajardo, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. The Journal of Pediatrics [Internet]. 1990 Nov 1 [cited 2024 Aug 24];117(5):827–9. DOI: 10.1016/s0022-3476(05)83352-9. PMID: 2121951
Koning S. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002 Jan 26;324(7331):203–3. DOI: 10.1136/bmj.324.7331.203. PMID: 11809642
Koning S, van der Wouden JC, Chosidow O, Twynholm M, Singh KP, Scangarella N, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008 May;158(5):1077–82. DOI: 10.1111/j.1365-2133.2008.08485.x. PMID: 18341664
Kuniyuki S, Nakano K, Maekawa N, Suzuki S. Topical Antibiotic Treatment of Impetigo with Tetracycline. J Dermatol. 2005 Oct;32(10):788–92. DOI: 10.1111/j.1346-8138.2005.tb00846.x. PMID: 16361729
McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol. 1990 May;22(5):883–5. DOI: 10.1016/0190-9622(90)70118-2. PMID: 2112166
Mertz. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol [Internet]. 2020 [cited 2024 August 24th];125(8). PMID: 2502950
Molting S, Strauss WB. Treatment of Impetigo and Ecthyma. Int J Dermatol. 1988 Dec;27(10):716–9. DOI: 10.1111/j.1365-4362.1988.tb01273.x. PMID: 3069760
Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, et al. Topical Retapamulin Ointment, 1%, versus Sodium Fusidate Ointment, 2%, for Impetigo: A Randomized, Observer-Blinded, Noninferiority Study. Dermatology. 2007;215(4):331–40. DOI: 10.1159/000107776. PMID: 17911992
Rosen T, Albareda N, Rosenberg N, Alonso FG, Roth S, Zsolt I, et al. Efficacy and safety of ozenoxacin cream for treatment of adult and pediatric patients with impetigo. JAMA Dermatol. 2018 Jul 1;154(7):806. DOI: 10.1001/jamadermatol.2018.1103. PMID: 29898217.
Dharani Sudha G, Nirmala P, Ramanathan R, Samuel V. Comparative study of efficacy and safety of azithromycin alone and in combination with probiotic in the treatment of impetigo in children. Int J Curr Pharm Sci. 2017 November 14th;9(6):52–2. DOI: 10.22159/ijcpr.2017v9i6.23429. PMID: PMC7259577
Tong SY, Andrews RM, Kearns T, Gundjirryirr R, McDonald MI, Currie BJ, et al. Trimethoprim-sulfamethoxazole compared with benzathine penicillin for treatment of impetigo in Aboriginal children: A pilot randomised controlled trial. Paediatr Child Health. 2010 Mar 17;46(3):131–3. DOI: 10.1111/j.1440-1754.2010.01697.x. PMID: 20415992
Catalogue of Bias Collaboration. Spencer EA, Aronson JK, Nunan D, Heneghan C. Berkson's bias. In: Catalogue Of Bias 2018: https://catalogofbias.org/
Wang A, Menon R, Li T, Harris L, Harris IA, Naylor J, et al. Has the degree of outcome reporting bias in surgical randomized trials changed? A meta-regression analysis. ANZ J Surg. 2023 Jan;93(1-2):76-82. DOI: 10.1111/ans.18273. PMID: 36655339.
van der Steen JT, van den Bogert CA, van Soest-Poortvliet MC, Fazeli Farsani S, Otten RHJ, et al. Determinants of selective reporting: A taxonomy based on content analysis of a random selection of the literature. PLoS One. 2018 Feb 5;13(2):e0188247. DOI: 10.1371/journal.pone.0188247. PMID: 29401497
Dal-Ré R, Marušić A. Prevention of selective outcome reporting: let us start from the beginning. Eur J Clin Pharmacol. 2016 Oct;72(10):1283-1288. DOI: 10.1007/s00228-016-2107-6. PMID: 27473455
Ratib S, Wilkes SR, Grainge MJ, Thomas KS, Tobinska C, Williams HC. Is there an association between study size and reporting of study quality in dermatological clinical trials? A meta-epidemiological review. Br J Dermatol. 2017 Jun;176(6):1657-1658. DOI: 10.1111/bjd.15372. PMID: 28369781
Sá KMM, Rodrigues JC, da Silva LB, Santos GM, Colovati MES, Martimbianco ALC. Quality of systematic reviews on the treatment of vesiculobullous skin diseases. A meta-epidemiological study. An Bras Dermatol. 2024 Mar-Apr;99(2):223-232. DOI: 10.1016/j.abd.2023.06.003. PMID: 37985301
Martimbianco ALC, Sá KMM, Santos GM, Santos EM, Pacheco RL, Riera R. Most Cochrane systematic reviews and protocols did not adhere to the Cochrane's risk of bias 2.0 tool. Rev Assoc Med Bras. 2023 Feb 20;69(3):469-472. DOI: 10.1590/1806-9282.20221593. PMID: 36820779
Minozzi S, Cinquini M, Gianola S, Gonzalez-Lorenzo M, Banzi R. The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application. J Clin Epidemiol. 2020 Oct;126:37-44. DOI: 10.1016/j.jclinepi.2020.06.015. PMID: 32562833
Wang Y, Keitz S, Briel M, Glasziou P, Brignardello-Petersen R, Siemieniuk RAC, et al. Development of ROBUST-RCT: Risk Of Bias instrument for Use in SysTematic reviews-for Randomised Controlled Trials. BMJ. 2025 Mar 25;388:e081199. DOI: 10.1136/bmj-2024-081199. PMID: 40132800
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. DOI: 10.7326/0003-4819-158-3-201302050-00583. PMID: 23295957
Schulz KF, Altman DG, Moher D; for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332. PMID: 20332509
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Juliana Cavaleiro Rodrigues, Kamilla Mayr Martins Sá, Giullia Carvalho Mangas Lopes, Marcella Cosmo Piovesan, Elaine Marcílio Santos, Ana Luiza Martimbianco
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
